Shares of Neogen Corporation (NASDAQ:NEOG – Get Free Report) have been assigned a consensus recommendation of “Hold” from the six brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $10.6667.
A number of analysts have recently issued reports on the stock. Piper Sandler reissued a “neutral” rating and issued a $10.00 price target (up from $6.50) on shares of Neogen in a research report on Monday, January 12th. Wall Street Zen lowered shares of Neogen from a “buy” rating to a “hold” rating in a research note on Saturday, January 10th. Weiss Ratings restated a “sell (e+)” rating on shares of Neogen in a report on Monday, December 29th. Guggenheim reiterated a “buy” rating and set a $12.00 price objective (up from $8.00) on shares of Neogen in a report on Friday, January 9th. Finally, CJS Securities upgraded Neogen from a “market perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a research note on Wednesday, December 10th.
View Our Latest Stock Report on NEOG
Hedge Funds Weigh In On Neogen
Neogen Price Performance
NEOG opened at $10.22 on Friday. The firm has a market capitalization of $2.22 billion, a P/E ratio of -3.69 and a beta of 1.96. The stock has a fifty day moving average of $7.74 and a 200-day moving average of $6.38. The company has a quick ratio of 2.80, a current ratio of 3.91 and a debt-to-equity ratio of 0.38. Neogen has a 12-month low of $3.87 and a 12-month high of $11.76.
Neogen (NASDAQ:NEOG – Get Free Report) last posted its quarterly earnings results on Thursday, January 8th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.03. Neogen had a positive return on equity of 2.14% and a negative net margin of 68.47%.The firm had revenue of $224.69 million for the quarter, compared to analyst estimates of $208.50 million. During the same period in the previous year, the firm earned $0.11 earnings per share. Neogen’s quarterly revenue was down 2.9% on a year-over-year basis. Equities analysts forecast that Neogen will post 0.38 EPS for the current fiscal year.
About Neogen
Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.
In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.
Read More
- Five stocks we like better than Neogen
- Stock market legend warns: “An Ominous Day Is Coming for the Markets…”
- Another reason you need to own gold… [running out]
- Trump’s Final Shocking Act Begins February 24
- NEW: Gold makes history
- Deutsche Bank Just Raised Their Gold Target to $6,000
Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.
